| Market Capitalization (Millions $) |
15,706 |
| Shares
Outstanding (Millions) |
104 |
| Employees |
2,000 |
| Revenues (TTM) (Millions $) |
3,374 |
| Net Income (TTM) (Millions $) |
706 |
| Cash Flow (TTM) (Millions $) |
3 |
| Capital Exp. (TTM) (Millions $) |
33 |
Business Description
Neurocrine Biosciences Inc.
is a biopharmaceutical company that is focused on the research, development, and commercialization of treatments for neurological and endocrine-related diseases and disorders.
The company was founded in 1992 and is headquartered in San Diego, California.
Neurocrine Biosciences has a strong portfolio of products in various stages of development, including several that have received regulatory approval in the United States and other international markets.
One of its most successful products is Ingrezza, a drug that is used to treat tardive dyskinesia, a condition characterized by involuntary muscle movements.
Ingrezza was approved by the FDA in 2017 and has since become the leading drug in the market for the treatment of tardive dyskinesia.
Neurocrine Biosciences also has several other products in its pipeline, including Ongentys, a drug for the treatment of Parkinsones disease, which was approved by the FDA in 2020.
In addition to its focus on commercializing drugs for neurological and endocrine disorders, Neurocrine Biosciences also invests heavily in research and development.
The company has a strong commitment to discovering and developing new therapies for conditions that have few or no treatment options.
Overall, Neurocrine Biosciences Inc.
is a leading biopharmaceutical company that has been making significant contributions to the field of medicine by developing innovative treatments for neurological and endocrine-related disorders.
With a strong pipeline of products and a commitment to research and development, the company is well-positioned for future growth and success.
Company Address: 6027 Edgewood Bend Court San Diego 92130 CA
Company Phone Number: 617-7600 Stock Exchange / Ticker: NASDAQ NBIX
|
2.8% 
184.08 %